Guggenheim analyst Yatin Suneja reiterated a Buy rating and $50.00 price target on Abivax (NASDAQ: ABVX).The analyst commented: "Key takeaways ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE